Drug Trial Radar · NCT01297920
Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%
Last checked: Nov 19, 2026Latest source record: Jul 4, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,062
Actual
Start
Mar 2011
Primary completion
Jun 2012
Study completion Jun 2012
Sponsor
- Lead sponsor
- Alcon ResearchIndustry
- Sponsor type
- Industry
- First posted
- Feb 17, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the safety and efficacy of a new ophthalmic suspension (Brinz/Brim) in lowering intraocular pressure (IOP) relative to its individual active components in subjects with open-angle glaucoma and/or ocular hypertension.
Conditions
- Open-Angle Glaucoma
- Ocular Hypertension
Interventions
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspensionDrug
Brinzolamide ophthalmic suspension, 1%Drug
Brimonidine tartrate ophthalmic solution, 0.2%Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Intraocular Pressure (IOP) at Each Assessment Timepoint (8 AM, +2 h, +7 h, and +9 h) at Month 3Time frame: Month 3
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.